NASDAQ:SABS SAB Biotherapeutics (SABS) Stock Price, News & Analysis $2.87 -0.06 (-2.05%) (As of 07/5/2024 ET) Add Compare Share Share Today's Range$2.80▼$2.9050-Day Range$2.57▼$4.2952-Week Range$2.36▼$10.50Volume1,965 shsAverage Volume10,856 shsMarket Capitalization$26.49 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get SAB Biotherapeutics alerts: Email Address SAB Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside353.0% Upside$13.00 Price TargetShort InterestHealthy0.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.08) to ($3.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector544th out of 879 stocksBiological Products, Except Diagnostic Industry81st out of 149 stocks 3.4 Analyst's Opinion Consensus RatingSAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSAB Biotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about SAB Biotherapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.46% of the float of SAB Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSAB Biotherapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SAB Biotherapeutics has recently increased by 0.88%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSAB Biotherapeutics does not currently pay a dividend.Dividend GrowthSAB Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SABS. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for SAB Biotherapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for SABS on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders26.46% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.82% of the stock of SAB Biotherapeutics is held by institutions.Read more about SAB Biotherapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SAB Biotherapeutics are expected to grow in the coming year, from ($4.08) to ($3.26) per share.Price to Book Value per Share RatioSAB Biotherapeutics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about SAB Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… Click here to register now. About SAB Biotherapeutics Stock (NASDAQ:SABS)SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.Read More SABS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SABS Stock News HeadlinesJuly 1, 2024 | americanbankingnews.comSAB Biotherapeutics (NASDAQ:SABS) versus Vitro Diagnostics (OTCMKTS:VODG) Financial SurveyJune 20, 2024 | globenewswire.comSAb Biotherapeutics Rebrands as SAB BIOJuly 6, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… June 18, 2024 | globenewswire.comSAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific SessionsMay 30, 2024 | globenewswire.comSAB Biotherapeutics Announces Departure of Chief Financial OfficerMay 25, 2024 | bizjournals.comPharma company moves headquarters from Midwest to Miami BeachMay 21, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsMay 21, 2024 | markets.businessinsider.comSAB Biotherapeutics: Strong Buy Rating on Robust Financials and Promising Diabetes Drug DevelopmentJuly 6, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 21, 2024 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesMay 21, 2024 | markets.businessinsider.comSAB Biotherapeutics Gets FDA Clearance To Advance Phase 1 Trial Of SAB-142 In Type-1 DiabetesMay 21, 2024 | globenewswire.comFDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsMay 20, 2024 | globenewswire.comSAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesMay 6, 2024 | globenewswire.comSAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsApril 17, 2024 | msn.comSAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36April 16, 2024 | msn.comSAB Leaps on Completing Latest CohortApril 16, 2024 | globenewswire.comSAB Biotherapeutics Provides SAB-142 Trial UpdateApril 8, 2024 | globenewswire.comSAB Biotherapeutics to Present at INNODIA Annual MeetingSee More Headlines Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today7/06/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:SABS CUSIPN/A CIK1833214 Webwww.bigcypressaccorp.com Phone605-679-6980FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$25.00 Low Stock Price Target$6.00 Potential Upside/Downside+353.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,190,000.00 Net Margins-1,531.26% Pretax Margin-1,531.26% Return on Equity-109.90% Return on Assets-72.78% Debt Debt-to-Equity Ratio0.06 Current Ratio5.65 Quick Ratio5.65 Sales & Book Value Annual Sales$2.24 million Price / Sales11.83 Cash FlowN/A Price / Cash FlowN/A Book Value$6.21 per share Price / Book0.46Miscellaneous Outstanding Shares9,230,000Free Float6,787,000Market Cap$26.49 million OptionableNot Optionable Beta0.68 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Samuel J. Reich (Age 49)CEO & Executive Chairman Comp: $363.2kDr. Eddie Joe Sullivan Ph.D. (Age 57)Co-Founder, President & Director Comp: $402.56kMs. Christine E. Hamilton M.B.A. (Age 68)Co-Founder & Independent Director Comp: $25kMr. Michael George King Jr. (Age 63)EVP & CFO Comp: $60.58kDr. Christoph Bausch M.B.A. (Age 53)Ph.D., Executive VP & COO Comp: $443.2kDr. Alexandra Kropotova M.B.A. (Age 51)M.D., Executive VP & Chief Medical Officer Comp: $774.45kDr. Edward D. Hamilton D.V.M.Co-Founder & Board ObserverDr. Carlos N. Carillo Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsVerastemNASDAQ:VSTMSangamo TherapeuticsNASDAQ:SGMOCurisNASDAQ:CRISFortress BiotechNASDAQ:FBIOBolt BiotherapeuticsNASDAQ:BOLTView All CompetitorsInsiders & InstitutionsBVF Inc. ILSold 8,260,456 shares on 5/16/2024Ownership: 9.944%Eddie Joe SullivanBought 1,740 shares on 12/7/2023Total: $1,531.20 ($0.88/share)Michael KingBought 5,000 shares on 11/30/2023Total: $4,500.00 ($0.90/share)Samuel J ReichBought 11,000 shares on 11/29/2023Total: $9,790.00 ($0.89/share)View All Insider TransactionsView All Institutional Transactions SABS Stock Analysis - Frequently Asked Questions How have SABS shares performed this year? SAB Biotherapeutics' stock was trading at $0.6875 at the beginning of 2024. Since then, SABS shares have increased by 317.5% and is now trading at $2.87. View the best growth stocks for 2024 here. How were SAB Biotherapeutics' earnings last quarter? SAB Biotherapeutics, Inc. (NASDAQ:SABS) issued its quarterly earnings data on Monday, May, 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.44. The company had revenue of $0.95 million for the quarter. SAB Biotherapeutics had a negative trailing twelve-month return on equity of 109.90% and a negative net margin of 1,531.26%. How do I buy shares of SAB Biotherapeutics? Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SABS) was last updated on 7/6/2024 by MarketBeat.com Staff From Our Partners50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SABS Stock Alerts